文献速递胃肠动力与功能性疾病

两项3期研究显示早期应答可预测艾沙度林对腹泻型肠易激综合征患者的持续应答

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
PubMed 文献 · Aliment Pharmacol Ther · 2017-03-22

本文为两项3期研究的事后分析,共随机2428例腹泻型肠易激综合征患者。第1个月复合应答率在艾沙度林100 mg组为24.6%、75 mg组为22.8%、安慰剂组为12.5%;第1个月应答者中,100 mg和75 mg组分别有77.8%和81.5%(第1-3个月)及70.7%和73.9%(第1-6个月)保持持续应答。结论认为早期临床应答与最长6个月的持续获益相关。

要点

  • 第1个月复合应答率:艾沙度林100 mg组24.6%、75 mg组22.8%、安慰剂组12.5%。
  • 第1个月应答者中,100 mg和75 mg组分别有70.7%和73.9%在第1-6个月保持持续应答。
  • 第1个月无应答者中,不足20%在第1-3个月或第1-6个月出现应答。

核心结论

  • 超过三分之二的第1个月应答者在艾沙度林治疗6个月内保持阳性应答,表明早期临床应答与腹泻型肠易激综合征患者最长6个月的持续获益相关。

研究设计与样本

  • 两项3期研究的事后分析,共随机2428例患者,计算第1个月复合应答率和充分缓解(AR)应答率,并按应答状态分层统计后续间隔的累积计数。

主要发现

  • 第1个月复合应答率:艾沙度林100 mg组24.6%、75 mg组22.8%、安慰剂组12.5%。
  • 第1个月应答者中,艾沙度林100 mg组和75 mg组分别有77.8%和81.5%在第1-3个月、70.7%和73.9%在第1-6个月保持持续应答。
  • 第1个月无应答者中,不足20%在第1-3个月或第1-6个月出现应答。
  • 充分缓解应答者比例在各时间间隔的分析中显示相似结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist, eluxadoline, is licensed in the USA for the treatment of irritable bowel syndrome with diarrhoea (IBS-D), based on the results of two large Phase 3 clinical trials. AIM: To understand the time course of treatment benefits with eluxadoline by comparing responder rates over the first month of treatment with responder rates over longer treatment intervals. METHODS: In this post hoc analysis of two Phase 3 studies, composite and adequate relief (AR) responder rates were calculated over month 1 and patients were stratified by their responder status. Cumulative counts over subsequent intervals (months 1-3, months 1-6, months 2 through 6) were tallied. RESULTS: The studies randomised 2428 patients. Over month 1, 24.6%, 22.8% and 12.5% of patients were composite responders with eluxadoline 100 mg, eluxadoline 75 mg and placebo respectively. For month 1 responders, 77.8% and 81.5% (over months 1-3) and 70.7% and 73.9% (over months 1-6) showed a continuous response with eluxadoline 100 mg and 75 mg respectively. [Correction added on 5 April 2017, after first online publication: The percentage for the responders over months 1-3 was previously wrong and has been corrected.] Of the month 1 nonresponders, <20% showed a response over months 1-3 or months 1-6. Similar results were seen for the analysis of proportions of AR responders over these time intervals. CONCLUSIONS: Over two-thirds of patients who respond over the first month retain a positive response over 6 months of treatment with eluxadoline, indicating that early clinical response to eluxadoline is associated with sustained benefits for up to 6 months in patients with IBS-D.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chey WD, Dove LS, Andrae DA, et al. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies. Aliment Pharmacol Ther. 2017. PMID: 28326568. doi:10.1111/apt.14031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。